|
1,944
|
| 15222 |
Csf3
|
|
decreases_activity of
|
quiescence
|
of d-HSC (LRC) by inducing injury signals
|
in vivo
|
| 16212 |
BM injury
|
|
decreases_activity of
|
quiescence
|
of d-HSC (LRC-HSC, CD34-CD150+CD48-CD135-KSL)
|
in vivo
|
| 16275 |
BM homeostasis
|
|
increases_activity of
|
quiescence
|
of d-HSC (LRC-HSC, CD34-CD150+CD48-CD135-KSL)
|
in vivo
|
|
19062086
|
|
1,952
|
| 15112 |
dormant-HSC (LRC-HSC, CD34-CD150+CD48-CD135-KSL)
|
|
increases_activity of
|
quiescence
|
about 100% are in G0 phase
|
in vivo
|
| 15698 |
active-HSC (non-LRC-HSC, CD34-CD150+CD48-CD135-KSL)
|
|
decreases_activity of
|
quiescence
|
about 83% are in G0 phase
|
in vivo
|
|
19062086
|
|
1,955
|
| 15152 |
LT-HSC (CD34(lo)CD135-Rho(lo)CD49b(lo)KSL)
|
|
increases_activity of
|
quiescence
|
Onset of division of LT-HSC with CD49b(lo) was delayed compared to IT-HSCs with CD49b(hi).
|
in vitro
|
| 15500 |
IT-HSC (CD34(lo)CD135-Rho(lo)CD49b(hi)KSL)
|
|
increases_activity of
|
quiescence
|
Onset of division of LT-HSC with CD49b(lo) was delayed compared to IT-HSCs with CD49b(hi).
|
in vitro
|
|
20074534
|
|
1,995
|
| 15865 |
My-bi-HSC (lower SP,KSL)
|
|
increases_activity of
|
quiescence
|
Ly-HSCs are more proliferative than My-HSCs.
|
in vivo
|
| 15867 |
transforming growth factor beta receptor signaling pathway
|
|
affects_activity of
|
quiescence
|
|
|
|
20207229
|
|
2,067
|
| 16651 |
Itch
|
|
increases_activity of
|
quiescence
|
|
in vivo
|
|
21478879
|
|
2,068
|
| 16654 |
Notch1
|
|
decreases_activity of
|
quiescence
|
if the intracellular domain of Notch1 is overexpressed
|
|
|
21478879
|
|
2,102
|
| 17152 |
Tek
|
|
increases_activity of
|
quiescence
|
through interaction with the niche
|
|
|
16151515
|
|
2,140
|
| 17705 |
HSC (CD34-CD135-CD150+CD48-KSL)
|
|
increases_activity of
|
quiescence
|
about 70% are in G0 phase
|
in vitro
|
| 17707 |
MPP (CD34+CD48-CD150+CD135-KSL)
|
|
decreases_activity of
|
quiescence
|
compared to the CD34- population; about 40% are in G0 phase
|
in vitro
|
| 17708 |
MPP (CD34+CD48+CD150-CD135+KSL)
|
|
decreases_activity of
|
quiescence
|
compared to the CD135- population; about 6% are in G0 phase
|
in vitro
|
| 17710 |
dormant-HSC (LRC-HSC, CD34-CD150+CD48-CD135-KSL)
|
|
increases_activity of
|
quiescence
|
|
in vivo
|
| 24260 |
MPP (CD34+CD48+CD150-CD135-KSL)
|
|
decreases_activity of
|
quiescence
|
compared to the CD135- population; about 9% are in G0 phase
|
in vitro
|
| 24261 |
MPP (CD34+CD48+CD150+CD135-KSL)
|
|
decreases_activity of
|
quiescence
|
compared to the CD135- population; about 18% are in G0 phase
|
in vitro
|
|
19062086
|
|
2,197
|
| 18456 |
HSC (SP,KSL)
|
|
increases_activity of
|
quiescence
|
only 2% are in cycle
|
|
|
15459755
|
|
2,569
|
| 24171 |
HSC (SP,KSL)
|
|
increases_activity of
|
quiescence
|
compared to HSC (non-SP,KSL)
|
|
| 24173 |
5-FU
|
|
decreases_activity of
|
quiescence
|
|
in vivo
|
| 24937 |
HSC (CD34-Mpl+KSL)
|
|
increases_activity of
|
quiescence
|
|
in vivo
|
| 37950 |
Mpl
|
|
increases_activity of
|
quiescence
|
|
in vivo
|
|
18371409
|
|
2,622
|
| 24910 |
TPO/MPL signaling
|
|
increases_activity of
|
quiescence
|
in HSC (CD34-Mpl+KSL)
|
in vivo
|
| 24913 |
Thpo
|
|
increases_activity of
|
quiescence
|
|
in vivo
|
| 24915 |
TPO/MPL signaling
|
|
increases_activity of
|
quiescence
|
in LT-HSC (SP,KSL)
|
in vivo
|
| 24917 |
Mpl
|
|
increases_activity of
|
quiescence
|
in HSC (CD34-Mpl+KSL)
|
in vivo
|
|
18371409
|
|
2,626
|
| 24949 |
Thpo
|
|
increases_activity of
|
quiescence
|
in LT-HSC (CD34-FLT3-KSL)
|
in vivo
|
|
18371408
|
|
2,628
|
| 24960 |
HSC (Tie2+SP,KSL)
|
|
increases_activity of
|
quiescence
|
compared to Tie2-cells; more than 90% of the cells after 5FU treatment are in G0 phase
|
in vivo
|
| 25032 |
Tie2/Ang1 signaling
|
|
increases_activity of
|
quiescence
|
in LT-HSC (Tie2+SP,KSL), overexpressing Ang1; 67% of the stem cells are in G0 phase of the cell cycle
|
in vivo
|
| 27951 |
Angpt1
|
|
increases_activity of
|
quiescence
|
in LT-HSC (Tie2+SP,KSL)
|
in vivo
|
| 37945 |
Tek
|
|
increases_activity of
|
quiescence
|
compared to Tie2-cells; more than 90% of the cells after 5FU treatment are in G0 phase
|
in vivo
|
|
15260986
|
|
2,656
|
| 25077 |
Sh2b3
|
|
decreases_activity of
|
quiescence
|
compared to WT or Mpl-/- cells. It is suggested that Lnk controls HSC quiescence through Mpl. and downregulation of JAK2
|
in vivo
|
| 25078 |
Mpl
|
|
increases_activity of
|
quiescence
|
compared to WT or Lnk-/- cells
|
in vivo
|
|
18618018
|
|
2,756
|
| 30917 |
BMP signaling pathway
|
|
decreases_activity of
|
quiescence
|
|
in vivo
|
| 37819 |
Bmpr1a
|
|
decreases_activity of
|
quiescence
|
|
in vivo
|
|
14574412
|
|
2,761
|
| 25581 |
CAR cell
|
|
decreases_activity of
|
quiescence
|
of LT-HSC (CD34-CD150+CD48-KSL)
|
in vivo
|
|
20850355
|
|
2,766
|
| 30461 |
CXCL12/CXCR4 signaling
|
|
increases_activity of
|
quiescence
|
|
|
| 30462 |
Cxcr4
|
|
increases_activity of
|
quiescence
|
|
|
|
17174120
|
|
2,827
|
| 26379 |
HSC (endCD150+CD48-KSL)
|
|
increases_activity of
|
quiescence
|
CD150+CD48-KSL cells isolated from endosteal BM region
|
in vivo
|
| 26380 |
HSC (centCD150+CD48-KSL)
|
|
increases_activity of
|
quiescence
|
CD150+CD48-KSL cells isolated from central BM region
|
in vivo
|
|
20631378
|
|
2,834
|
| 26172 |
canonical Wnt signaling pathway
|
|
increases_activity of
|
quiescence
|
of HSC (CD34(lo)KSL)
|
in vivo
|
| 26320 |
Dkk1
|
|
decreases_activity of
|
quiescence
|
of HSC (CD34(lo)KSL)
|
in vivo
|
|
18371452
|
|
2,878
|
| 26517 |
Wif1
|
|
decreases_activity of
|
quiescence
|
in HSC (KSL); if Wif1 is overexpressed in osteoblasts
|
in vivo
|
|
21652676
|
|
2,895
|
| 26598 |
Spp1
|
|
increases_activity of
|
quiescence
|
of HSC (KSL)
|
in vivo
|
|
15845900
|
|
2,992
|
| 27249 |
HSC (SP,Sca1+Lin-)
|
|
increases_activity of
|
quiescence
|
|
in vivo
|
|
8666936
|
|
2,995
|
| 27272 |
HSC (Thy1(lo)Sca1+Lin-Mac1-CD4-)
|
|
increases_activity of
|
quiescence
|
|
in vivo
|
|
7541305
|
|
3,018
|
| 27676 |
HSC (Thy1(lo)Rho(lo)KSL
|
|
increases_activity of
|
quiescence
|
|
in vivo
|
|
12393558
|
|
3,021
|
| 27675 |
HSC (Thy1(lo)Rho(hi)KSL
|
|
decreases_activity of
|
quiescence
|
|
in vivo
|
|
12393558
|
|
3,059
|
| 28071 |
HSC (Thy1(lo)Sca1+Lin-)
|
|
increases_activity of
|
quiescence
|
|
in vitro
|
|
2898810
|
|
3,111
|
| 28570 |
Stat5a
|
|
increases_activity of
|
quiescence
|
within the HSC (CD34-KSL) pool
|
in vivo
|
|
19258595
|
|
3,125
|
| 38401 |
Nfya
|
|
decreases_activity of
|
quiescence
|
in BM progenitors and precursors. Quiescent HSCs do not depend on NF-Y activity.
|
in vivo
|
|
22072554
|
|
3,148
|
| 28992 |
Kit
|
|
increases_activity of
|
quiescence
|
in LT-HSC (CD34-Flk2-KSL)
|
|
|
18250409
|
|
3,150
|
| 29008 |
Cdkn1a
|
|
increases_activity of
|
quiescence
|
of BM (lin-) cells
|
in vivo
|
|
10710306
|
HSC